Kura Oncology (KURA) Stock Price, News & Analysis

Company Overview

Kura Oncology, Inc. (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers. In addition to tipifarnib, Kura Oncology is developing a pipeline of targeted agents, including selective inhibitors of FGFRs, WEE1, and other kinases implicated in oncogenic signaling. Several of these programs are in early-stage clinical trials, and preclinical efforts aim to expand into combination strategies and additional genetic subsets of cancer.

Since its founding in 2011, Kura has built a multidisciplinary team of scientists and clinicians to drive its translational research efforts. Under the leadership of Chief Executive Officer Troy Wilson, the company has established strategic partnerships and secured funding to support its clinical development milestones. Kura’s board and management team bring extensive experience in oncology drug development, regulatory affairs, and commercialization, positioning the company to advance its novel therapies through late-stage trials.

Kura Oncology primarily operates in the United States, collaborating with leading cancer centers and research institutions to conduct and monitor its clinical studies. The company’s strategic focus on genetically defined patient populations aligns with broader trends toward precision oncology, aiming to deliver therapies that improve outcomes for patients with specific tumor profiles. Looking ahead, Kura plans to continue advancing its pipeline and exploring potential collaborations to broaden the reach of its targeted cancer treatments.

Key Stats

• Today's Range: $10.65 to $11.11
• 50-Day Range: $8.56 to $11.25
• 52-Week Range: $5.45 to $12.49
• Volume: 1.89 million shs
• Average Volume: 1.77 million shs
• Market Capitalization: $985.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.46
• Consensus Rating: Moderate Buy

Kura Oncology Stock Analysis - MarketRank™

Kura Oncology scored higher than 45% of companies evaluated by MarketBeat, and ranked 520th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Kura Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on no strong buy ratings, 10 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Kura Oncology has a consensus price target of $25.46, representing about 129.4% upside from its current price of $11.10.

Amount of Analyst Coverage

Kura Oncology has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Kura Oncology are expected to grow in the coming year, from ($3.45) to ($2.43) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kura Oncology is -3.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kura Oncology is -3.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Kura Oncology has a P/B Ratio of 5.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.80% of the float of Kura Oncology has been sold short.

Short Interest Ratio / Days to Cover

Kura Oncology has a short interest ratio ("days to cover") of 7.33.

Change versus previous month

Short interest in Kura Oncology has recently increased by 7.44%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kura Oncology does not currently pay a dividend.

Dividend Growth

Kura Oncology does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for Kura Oncology this week, compared to 6 articles on an average week.

Search Interest

Only 8 people have searched for KURA on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Kura Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Kura Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $834,003.00 in company stock.

Percentage Held by Insiders

7.60% of the stock of Kura Oncology is held by insiders.

Percentage Held by Institutions

Kura Oncology has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 7/04/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KURA
• CIK: 1422143
• Web: www.kuraoncology.com
• Phone: (858) 500-8800
• Fax: N/A
• Employees: 130
• Year Founded: 2007

Price Target and Rating

• Average Price Target for Kura Oncology: $25.46
• High Price Target: $40.00
• Low Price Target: $15.00
• Potential Upside/Downside: +129.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.69
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$278.67 million
• Net Margins: -411.19%
• Pretax Margin: -411.08%
• Return on Equity: -141.95%
• Return on Assets: -43.28%

Debt

• Debt-to-Equity Ratio: 0.09
• Current Ratio: 6.15
• Quick Ratio: 6.14

Sales & Book Value

• Annual Sales: $67.48 million
• Price / Sales: 14.60
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.00 per share
• Price / Book: 5.55

Miscellaneous

• Outstanding Shares: 88,770,000
• Free Float: 82,027,000
• Market Cap: $985.35 million
• Optionable: Optionable
• Beta: 0.35